MARIOTTINI, ALICE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.050
EU - Europa 3.186
AS - Asia 3.038
SA - Sud America 379
Continente sconosciuto - Info sul continente non disponibili 139
AF - Africa 125
OC - Oceania 34
Totale 10.951
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.945
RU - Federazione Russa 1.150
IT - Italia 1.089
CN - Cina 886
SG - Singapore 807
HK - Hong Kong 362
BR - Brasile 293
KR - Corea 288
VN - Vietnam 238
IE - Irlanda 187
FR - Francia 127
SE - Svezia 112
DE - Germania 104
IN - India 99
PL - Polonia 95
BD - Bangladesh 87
FI - Finlandia 84
NL - Olanda 77
CA - Canada 64
JP - Giappone 58
GB - Regno Unito 55
ID - Indonesia 47
JO - Giordania 41
AU - Australia 33
AR - Argentina 32
MA - Marocco 32
NG - Nigeria 27
MX - Messico 26
ES - Italia 24
TR - Turchia 23
CH - Svizzera 21
EC - Ecuador 19
IQ - Iraq 19
ZA - Sudafrica 19
IR - Iran 17
CO - Colombia 14
CI - Costa d'Avorio 13
EG - Egitto 12
UA - Ucraina 12
PH - Filippine 11
AT - Austria 9
MY - Malesia 9
SA - Arabia Saudita 9
UZ - Uzbekistan 9
BJ - Benin 7
PK - Pakistan 7
KE - Kenya 6
VE - Venezuela 6
LV - Lettonia 5
PY - Paraguay 5
DZ - Algeria 4
LT - Lituania 4
UY - Uruguay 4
CL - Cile 3
GR - Grecia 3
HN - Honduras 3
HU - Ungheria 3
JM - Giamaica 3
KZ - Kazakistan 3
MK - Macedonia 3
SK - Slovacchia (Repubblica Slovacca) 3
TN - Tunisia 3
BY - Bielorussia 2
CR - Costa Rica 2
CZ - Repubblica Ceca 2
IL - Israele 2
KG - Kirghizistan 2
LB - Libano 2
LI - Liechtenstein 2
NO - Norvegia 2
NP - Nepal 2
OM - Oman 2
PE - Perù 2
RO - Romania 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AZ - Azerbaigian 1
BB - Barbados 1
BE - Belgio 1
BG - Bulgaria 1
BH - Bahrain 1
BO - Bolivia 1
CY - Cipro 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
GD - Grenada 1
GE - Georgia 1
GT - Guatemala 1
IM - Isola di Man 1
IS - Islanda 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LC - Santa Lucia 1
MQ - Martinica 1
NZ - Nuova Zelanda 1
PA - Panama 1
PT - Portogallo 1
RS - Serbia 1
SC - Seychelles 1
Totale 10.810
Salva come PNG Salva come JPEG
Città #
Santa Clara 1.097
Singapore 624
Ashburn 544
Hong Kong 322
San Jose 322
Hefei 309
Seoul 287
Milan 233
Dublin 187
Beijing 136
Council Bluffs 123
Chandler 112
Fairfield 99
Florence 95
Los Angeles 93
Ho Chi Minh City 91
Rome 91
Warsaw 84
Kent 82
Lauterbourg 64
Buffalo 59
Tokyo 55
Hanoi 54
Munich 51
Moscow 50
Dallas 48
Altamura 45
Lawrence 45
The Dalles 44
Seattle 42
Boston 40
Mumbai 39
New York 37
Paris 35
São Paulo 34
Wilmington 33
Cambridge 32
Jakarta 32
Lappeenranta 32
Woodbridge 32
Princeton 31
Houston 30
Turku 28
Melbourne 27
Phoenix 27
Abuja 26
Chicago 26
Naples 26
Casablanca 25
Helsinki 24
Shanghai 24
Frankfurt am Main 22
Turin 22
Bengaluru 18
Bologna 18
Clifton 18
Orem 16
Da Nang 14
Modena 14
Abidjan 13
Brooklyn 13
Chennai 13
Johannesburg 13
Rio de Janeiro 13
Toronto 13
West Jordan 13
Atlanta 12
Catania 12
Genoa 12
Hamburg 12
Palermo 12
Bern 11
Guangzhou 11
London 11
Barcelona 10
Dearborn 10
Denver 10
Istanbul 10
Montreal 10
Trieste 10
Boardman 9
Medford 9
Quito 9
San Diego 9
Stockholm 9
Amsterdam 8
Belo Horizonte 8
Cairo 8
Gdansk 8
Pune 8
Venice 8
Verona 8
Ann Arbor 7
Cotonou 7
Manchester 7
Miano 7
Norwalk 7
Ottawa 7
Porto Alegre 7
San Francisco 7
Totale 6.671
Salva come PNG Salva come JPEG
Nome #
K index improves MS diagnosis and supports the differential diagnosis between MS and MS-like syndromes. 477
Disease reactivation following fingolimod withdrawal in multiple sclerosis: Two case reports. 233
The TCR Repertoire Reconstitution in Multiple Sclerosis: Comparing One-Shot and Continuous Immunosuppressive Therapies 228
Safety and efficacy of autologous hematopoietic stem cell transplantation following natalizumab discontinuation in aggressive Multiple Sclerosis 220
Clinical characteristics predicting relapses following disease modifying therapies discontinuation in multiple sclerosis: a monocentric cohort study 214
Spinal cord size as promising biomarker of disability outcomes after hematopoietic stem cell transplantation in multiple sclerosis 205
Effect of the COVID-19 pandemic on disease activity in multiple sclerosis patients treated with hematopoietic stem cell transplantation 205
Early Morbidity of Autologous Haematopoietic Stem Cell Transplantation in Multiple Sclerosis- A Real World Experience 204
Safety and effectiveness of the booster dose of mRNA COVID-19 vaccines in people with multiple sclerosis: A monocentric experience 198
Safety and tolerability of SARS-Cov-2 vaccination in patients with myasthenia gravis: A multicenter experience 195
Effect of disease-modifying treatments on antibody-mediated response to anti- COVID19 vaccination in people with multiple sclerosis 195
Clinical and paraclinical findings in a case series of MOGAD: Exploring the presence of perivenular brain white matter lesions 193
Successful switch to ofatumumab after liver injury associated with ocrelizumab treatment in multiple sclerosis: a case report 187
Neuropsychological assessment in aggressive multiple sclerosis treated with stem cell transplantation 184
Impact of autologous haematopoietic stem cell transplantation on disability and brain atrophy in secondary progressive multiple sclerosis 180
Intermediate-Intensity Autologous Hematopoietic Stem Cell Transplantation Reduces Serum Neurofilament Light Chains and Brain Atrophy in Aggressive Multiple Sclerosis. 180
Leptomeningeal enhancement in multiple sclerosis: a focus on patients treated with hematopoietic stem cell transplantation 179
Acute unilateral sixth cranial nerve palsy and headache as initial manifestations of carcinomatous meningitis. 177
Severe disease reactivation in two multiple sclerosis patients after natalizumab withdrawal was not halted by monthly administrations of cyclophosphamide - two case reports 175
Anti-SARS-Cov2 vaccination at the time of the COVID-19 pandemic: suspected adverse events reporting is the milestone of post-marketing surveillance 174
Efficacy of autologous hematopoietic stem cell transplantation in secondary progressive Multiple sclerosis 170
Investigating Serum sHLA-G Cooperation With MRI Activity and Disease-Modifying Treatment Outcome in Relapsing-Remitting Multiple Sclerosis 169
Cost and effectiveness of autologous haematopoietic stem cell transplantation and high-efficacy disease-modifying therapies in relapsing–remitting multiple sclerosis 168
Evaluation of dimethyl fumarate efficacy and safety in patients with relapsing remitting multiple sclerosis switching from other treatments 164
Autologous hematopoietic stem cell transplantation versus low-dose immunosuppression in secondary-progressive multiple sclerosis 163
Reconstitution of natural or vaccination-driven immunity after aHSCT in multiple sclerosis 162
Autologous Hematopoietic Stem Cell Transplantation in Active Multiple Sclerosis: A Real-world Case Series 161
Hematopoietic Stem Cell Transplantation in People With Active Secondary Progressive Multiple Sclerosis 160
Case report: 3D intracranial vessel wall MRI in Susac syndrome: potential relevance for diagnosis and therapeutic management 159
Sustained disease remission in multiple sclerosis after autologous haematopoietic stem cell transplantation. The Italian experience 158
Comparative long term efficacy of beta interferons and azathioprine in relapsing-remitting Multiple sclerosis: single center retrospective 25 year evaluation 156
Disease Modifying Strategies in Multiple Sclerosis: New Rays of Hope to Combat Disability? 154
COVID-19 in patients with aggressive MS treated with aHSCT: a multi-center study 150
Incidence of malignant neoplasms and mortality in people affected by multiple sclerosis in the epoch of disease-modifying treatments: a population-based study on Tuscan residents 150
Impact of autologous haematopoietic stem cell transplantation on fertility in aggressive multiple sclerosis 148
CNS inflammation during relapsing remitting multiple sclerosis (RRMS): a molecular and cellular analysis of ex vivo CSF T lymphocyte expansions 147
Real Life comparative evaluation of dimethyl fumarate efficacy and tolerability in relapsing remitting multiple sclerosis patients switching from other treatments 146
Sustained disease remission after discontinuation of disease modifying treatments in relapsing-remitting multiple sclerosis. 145
Antibody-mediated cell depletion therapies in multiple sclerosis 143
Management of viral reactivation in multiple sclerosis patients after autologous transplantation with BEAM/ATG conditioning regimen 141
Hematopoietic Stem Cell Transplantation for the Treatment of Autoimmune Neurological Diseases: An Update 140
Prevalence of disability improvement as a potential outcome for multiple sclerosis trials 136
Long-Term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis 134
Immunosenescence and Autoimmunity: Exploiting the T-Cell Receptor Repertoire to Investigate the Impact of Aging on Multiple Sclerosis 133
Challenges in Diagnosis of COVID-19 Pneumonia under Ocrelizumab and De-Risking Strategies in Multiple Sclerosis—The Elephant Is (Still) in the Room 133
Haematopoietic Stem Cell Transplantation for the Treatment of Multiple Sclerosis: Recent Advances 129
Soluble factor profile in Natalizumab treated MS patients: increased Th1 promoting factors and sHLAg 128
Low positive predictive value of Multiple Sclerosis diagnostic criteria in demyelinating syndromes with red flags of better explanation. 127
Purely myeloablative conditioning regimen in aggressive multiple sclerosis: two case reports 125
Exploring the therapeutic potential of autologous hematopoietic stem cell transplantation in progressive multiple sclerosis—a systematic review 124
Magnetic Resonance intracranial Vessel Wall Imaging (VWI) in Susac Syndrome: potential relevance for diagnosis and therapeutic management. 124
Intermediate intensity regimen in autologous HSCT for severe multiple sclerosis: a large, single center experience 124
intermediate intensity regimen in autologous HSCT for severe Multiple Sclerosis: a a large, single center experience 122
Autologous haematopoietic stem cell transplantation for multiple sclerosis in the UK: A 20‐year retrospective analysis of activity and haematological outcomes from the British Society of Blood and Marrow Transplantation and Cellular Therapy (BSBMTCT) 121
Immune cell reconstitution following autologous hematopoietic stem cell transplantation in multiple sclerosis 119
Impact of new DMAs on the safety profile of patients undergoing autologous haematopoietic stem cell transplantation for Multiple Sclerosis 119
Safety profile of autologous haematopoietic stem cell transplantation following natalizumab therapy in aggressive forms of multiple sclerosis 117
Relevance of Pathogenetic Mechanisms to Clinical Effectiveness of B-Cell-Depleting Monoclonal Antibodies in Multiple Sclerosis 115
The role of chemotherapy in hematopoietic stem cell transplantation for autoimmune disorders: From lymphoablative to myeloablative conditioning protocols 114
Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis and neuromyelitis optica spectrum disorder — recommendations from ECTRIMS and the EBMT 114
Preface 108
Should autologous hematopoietic stem cell transplantation be offered as a first-line disease modifying therapy to patients with multiple sclerosis? 106
Thymic hyperplasia after autologous hematopoietic stem cell transplantation in multiple sclerosis: a case series 103
Haematopoietic Stem Cell Transplantation for Multiple Sclerosis: Current Status 102
Comparative efficacy of subcutaneous versus intravenous natalizumab on annualized relapse rate: a post-hoc analysis of the REFINE study 101
Effectiveness of Autologous Hematopoietic Stem Cell Transplantation versus Alemtuzumab and Ocrelizumab in Relapsing Multiple Sclerosis: A Single Center Cohort Study 98
Non-inferiority analysis of subcutaneous versus intravenous 300 mg monthly natalizumab administration: A post hoc analysis of the REFINE study 98
CD20+ T Cells in Multiple Sclerosis: From Pathogenesis to Treatment-Induced Depletion 95
Aggressive MS and Autologous HSCT: A review on behalf of the Autoimmune Diseases Working Party of the European Society for Blood and Marrow Transplantation 91
Autologous haematopoietic stem cell transplantation affects long-term progression independent of relapse activity in aggressive multiple sclerosis: a comparative matched study 69
Cell phenotype classification by NMR spectroscopy of intact cell lines 46
BEAM/ATG or cyclophosphamide/ATG as conditioning regimen in autologous haemopoietic stem cell transplantation for multiple sclerosis: a retrospective analysis of the EBMT autoimmune diseases working party 38
Should autologous HSCT be a first-line option in highly active MS: YES 37
Real-world effectiveness of autologous haematopoietic stem cell transplantation for multiple sclerosis in the UK 28
Phenotype Classification of Intact Cells by NMR Spectroscopy through Machine Learning Approaches 16
Totale 10.951
Salva come PNG Salva come JPEG
Categoria #
all - tutte 32.478
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 32.478
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022188 0 0 8 9 2 8 5 33 18 7 32 66
2022/2023683 44 112 45 34 35 126 104 36 102 1 27 17
2023/2024631 16 75 69 35 53 47 24 106 29 66 77 34
2024/20253.545 126 327 201 503 828 561 109 230 145 96 167 252
2025/20264.907 547 666 609 523 429 144 517 192 261 309 215 495
2026/2027582 192 177 213 0 0 0 0 0 0 0 0 0
Totale 10.951